Athera Biotechnologies AB

About Us

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach. Athera’s vision is to develop recombinant Annexin A5 for prevention of complications in patients with peripheral artery disease (PAD) undergoing vascular surgery. The project is currently in preclinical phase. PC-mAb from Athera is in late preclinical development, using a unique fully human monoclonal antibody. PC-mAb is being developed to restore cardio-protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. Athera, a Swedish company, is part of the Karolinska Development AB (publ) portfolio.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Athera elects new Chairman of the Board and moves to new premises

Thu, Sep 19, 2013 08:00 CET

STOCKHOLM, SWEDEN –Sept 19, 2013. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that Gunnar Olsson, former head of the global CV/GI team in AstraZeneca, has been elected new Chairman of the Board. Earlier this year, Tomas Odergren, VP Clinical Development at Karolinska Development AB, joined the Board of Directors.The extraordinary shareholders meeting in Athera has elected Gunnar Olsson new Chairman of the Board after Per Sjöberg, who has been leading the company for eight years. Dr Olsson joins Athera after 24 years in AstraZeneca, where he has

Athera and Medirista sign agreement to transfer the Annexin A5 project

Fri, Aug 23, 2013 09:30 CET

STOCKHOLM, SWEDEN – Aug 23, 2013. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that the rights to the recombinant Annexin A5 have been transferred to Medirista AB. Medirista is a biotech company owned by the original innovators of the Annexin A5 project, Johan and Anna Frostegård. The whole patent portfolio together with key preclinical assets have been transferred. Athera will continue its focus on development of the lead product candidate, the fully human antibody in atherosclerosis.Recombinant Annexin A5 has been developed to preclinical stage

Low levels of anti-PC predict vein graft failure

Thu, Oct 25, 2012 13:00 CET

STOCKHOLM, SWEDEN – October 25, 2012. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that results from a new study were presented at the Pacific Northwest Vascular Society Annual Meeting in Vancouver, Canada. The data shows that low levels of plasma anti-PC, measured with Athera’s CVDefine® kit, are associated with a high risk for vein graft failure after bypass surgery.It is known from previous published studies that low plasma levels of antibodies against phosphorylcholine (anti-PC) are linked to poor prognosis in acute heart attack patients, as

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Athera elects new Chairman of the Board and moves to new premises

Athera and Medirista sign agreement to transfer the Annexin A5 project

Low levels of anti-PC predict vein graft failure